Completed PHASE2 INTERVENTIONAL 2-arm NCT01089608

Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis

Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis (Pilot Phase II Clinical Study, Multicentre, Randomised, Double Masked, Comparative, 2 X 40 Patients)

Sponsor: Keyrus Biopharma

Conditions Blepharitis

Interventions Azithromycin Povidone

Updated 6 times since 2017 Last updated: Nov 3, 2014 Started: Mar 31, 2010 Primary completion: Jun 30, 2012 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01089608, this PHASE2 trial focuses on Blepharitis and remains completed. Sponsored by Keyrus Biopharma, it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
May 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — May 2017 [monthly]

Completed PHASE2

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Keyrus Biopharma
Laboratoires Thea
VEEDA

Data source: Laboratoires Thea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France